BioAge inks option agreement for Chinese biotech's obesity asset on heels of earlier APJ agonist setback
Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss space. The Bay Area biotech has entered an option agreement with Chinese firm JiKang Therapeutics to potentially license a new apelin receptor (APJ) agonist nanobody.
Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss space. The Bay Area biotech has entered an option agreement with Chinese firm JiKang Therapeutics to potentially license a new apelin receptor (APJ) agonist nanobody.
